Drug-induced uveitis

被引：51
作者：
London N.J.S. [1 ]
Garg S.J. [2 ]
Moorthy R.S. [3 ,4 ]
Cunningham Jr. E.T. [5 ,6 ]
机构：
[1] Retina Consultants San Diego, 9850 Genesee Avenue, Suite 700, La Jolla
[2] MidAtlantic Retina, The Retina Service of Wills Eye Institute, Thomas Jefferson University, 840 Walnut Street, Suite 1020, Philadelphia
[3] St. Vincent Hospital and Health Services, Indianapolis
[4] Indiana University School of Medicine, Indianapolis
[5] Department of Ophthalmology, California Pacific Medical Center, San Francisco
[6] Department of Ophthalmology, Stanford University School of Medicine, Stanford
来源：
Journal of Ophthalmic Inflammation and Infection | / 3卷 / 1期
关键词：
Bevacizumab; Uveitis; Ranibizumab; Topical Corticosteroid; Latanoprost;
D O I：
10.1186/1869-5760-3-43
中图分类号：
学科分类号：
摘要：
A number of medications have been associated with uveitis. This review highlights both well-established and recently reported systemic, topical, intraocular, and vaccine-associated causes of drug-induced uveitis, and assigns a quantitative score to each medication based upon criteria originally described by Naranjo and associates. © 2013 London et al.
引用
收藏
页码：1 / 18
相关论文
共 215 条
[1]  
Moorthy, R.S., Valluri, S., Jampol, L.M., Drug-induced uveitis (1998) Surv Ophthalmol, 42, pp. 557-570
[2]  
Cunningham Jr., E.T., Pasadhika, S., Suhler, E.B., Zierhut, M., Drug-induced inflammation in patients on TNFα inhibitors (2012) Ocul Immunol Inflamm, 20, pp. 2-5
[3]  
Cunningham Jr., E.T., Zierhut, M., TNF inhibitors for uveitis: Balancing efficacy and safety (2010) Ocul Immunol Inflamm, 18, pp. 421-423
[4]  
Naranjo, C.A., Busto, U., Sellers, E.M., Sandor, P., Ruiz, I., Roberts, E.A., Janecek, E., Greenblatt, D.J., A method for estimating the probability of adverse drug reactions (1981) Clin Pharmacol Ther, 30, pp. 239-245
[5]  
Lalezari, J.P., Drew, W.L., Glutzer, E., James, C., Miner, D., Flaherty, J., Fisher, P.E., Jaffe, H.S., (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): Results of a phase I/II study of a novel antiviral nucleotide analogue (1995) J Infect Dis, 171, pp. 788-796
[6]  
Lalezari, J.P., Cidofovir: A new therapy for cytomegalovirus retinitis (1997) J Acquir Immune Defic Syndr Hum Retrovirol, 14 (SUPPL. 1), pp. S22-S26
[7]  
Ho, H.T., Woods, K.L., Bronson, J.J., De Boeck, H., Martin, J.C., Hitchcock, M.J., Intracellular metabolism of the antiherpes agent (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (1992) Mol Pharmacol, 41, pp. 197-202
[8]  
Chavez-de la Paz, E., Arevalo, J.F., Kirsch, L.S., Munguia, D., Rahhal, F.M., De Clercq, E., Freeman, W.R., Anterior nongranulomatous uveitis after intravitreal HPMPC (cidofovir) for the treatment of cytomegalovirus retinitis. Analysis and prevention (1997) Ophthalmology, 104, pp. 539-544
[9]  
Kirsch, L.S., Arevalo, J.F., De Clercq, E., Chavez de la Paz, E., Munguia, D., Garcia, R., Freeman, W.R., Phase I/II study of intravitreal cidofovir for the treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome (1995) Am J Ophthalmol, 119, pp. 466-476
[10]  
Tseng, A.L., Mortimer, C.B., Salit, I.E., Iritis associated with intravenous cidofovir (1999) Ann Pharmacother, 33, pp. 167-171
12345678910